| scholarly article | Q13442814 |
| P50 | author | René Bernards | Q20518809 |
| Sjaak Neefjes | Q77086760 | ||
| Peter Ten Dijke | Q87987980 | ||
| Lodewyk F A Wessels | Q89966632 | ||
| Ultan McDermott | Q39992201 | ||
| Chong Sun | Q55446041 | ||
| P2093 | author name string | Fumihiro Tanaka | |
| Ramon Salazar | |||
| Wipawadee Grernrum | |||
| Hidetaka Uramoto | |||
| Paul Roepman | |||
| Theo Knijnenburg | |||
| Floris H Groenendijk | |||
| Michael Hölzel | |||
| Roderick L Beijersbergen | |||
| Sidong Huang | |||
| Wouter Nijkamp | |||
| Andreas Schlicker | |||
| Mathew Garnett | |||
| Lorenza Mittempergher | |||
| Anirudh Prahallad | |||
| P2860 | cites work | Bioconductor: open software development for computational biology and bioinformatics | Q21194861 |
| ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome | Q24313063 | ||
| A large-scale RNAi screen in human cells identifies new components of the p53 pathway | Q24319883 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| NCBI GEO: archive for functional genomics data sets--10 years on | Q24610731 | ||
| Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer | Q24616117 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer | Q24644945 | ||
| The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 | ||
| TopHat: discovering splice junctions with RNA-Seq | Q24655505 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors | Q27851431 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. | Q27851590 | ||
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling | Q27851628 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Epithelial-mesenchymal transitions in development and disease | Q27860630 | ||
| A system for stable expression of short interfering RNAs in mammalian cells | Q27860875 | ||
| CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity | Q28294122 | ||
| Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue | Q28742831 | ||
| affy--analysis of Affymetrix GeneChip data at the probe level | Q29547353 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations | Q29614275 | ||
| Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Q29615030 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| Non-Smad pathways in TGF-beta signaling | Q29620040 | ||
| TGF-β sensitivity is determined by N-linked glycosylation of the type II TGF-β receptor | Q30416553 | ||
| A versatile assay for high-throughput gene expression profiling on universal array matrices | Q31056777 | ||
| DEGseq: an R package for identifying differentially expressed genes from RNA-seq data | Q33512293 | ||
| EMT is the dominant program in human colon cancer | Q33798739 | ||
| NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome | Q34031980 | ||
| Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer | Q34062558 | ||
| TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer | Q34100276 | ||
| Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes | Q34100400 | ||
| Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence | Q34196515 | ||
| MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas | Q34210977 | ||
| The mammalian Mediator complex and its role in transcriptional regulation | Q34419211 | ||
| Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays | Q35103313 | ||
| Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. | Q36073367 | ||
| Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects | Q36235769 | ||
| An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors | Q38315892 | ||
| Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. | Q39996225 | ||
| Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. | Q54613561 | ||
| The Dip Test of Unimodality | Q55894425 | ||
| Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer | Q56601042 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mediator complex subunit 12 | Q21988276 |
| P304 | page(s) | 937-50 | |
| P577 | publication date | 2012-11-21 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling | |
| P478 | volume | 151 |
| Q92988209 | A Brief Review about the Role of Nanomaterials, Mineral-Organic Nanoparticles, and Extra-Bone Calcification in Promoting Carcinogenesis and Tumor Progression |
| Q36714160 | A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome. |
| Q53069742 | A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. |
| Q35438912 | A functional landscape of resistance to ALK inhibition in lung cancer |
| Q39195814 | A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells |
| Q28540936 | A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines |
| Q94552673 | A putative competing endogenous RNA network in cisplatin-resistant lung adenocarcinoma cells identifying potentially rewarding research targets |
| Q38148583 | Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. |
| Q64231562 | Afadin cooperates with Claudin-2 to promote breast cancer metastasis |
| Q55068795 | Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. |
| Q55309854 | Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer. |
| Q34477405 | Applications of RNA interference high-throughput screening technology in cancer biology and virology |
| Q64064834 | Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy |
| Q42318744 | Bringing light into gene regulation in hematopoietic stem cells by the Mediator complex |
| Q35944737 | Bufalin inhibits TGF-β-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-β receptors. |
| Q59129029 | CARM1 methylates MED12 to regulate its RNA-binding ability |
| Q61800386 | CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary |
| Q37301779 | CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma |
| Q29616694 | Cancer drug resistance: an evolving paradigm |
| Q91959503 | Cardiac Reprogramming Factors Synergistically Activate Genome-wide Cardiogenic Stage-Specific Enhancers |
| Q92917045 | Chemotherapy and Inflammatory Cytokine Signalling in Cancer Cells and the Tumour Microenvironment |
| Q38708220 | Chronic lymphocytic leukemia: Time to go past genomics? |
| Q91286978 | Circular RNA cESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-β signalling |
| Q38504491 | Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance. |
| Q26797238 | Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway |
| Q37268937 | Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types |
| Q38359194 | Compromised MAPK signaling in human diseases: an update |
| Q37075390 | Coordinate transcriptional and translational repression of p53 by TGF-β1 impairs the stress response |
| Q36365503 | Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition |
| Q37285973 | Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer. |
| Q53522728 | Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis. |
| Q54858547 | Downregulation of Lnc-Spry1 mediates TGF-β-induced epithelial-mesenchymal transition by transcriptional and posttranscriptional regulatory mechanisms. |
| Q33938441 | Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer |
| Q38218657 | Drug resistance to targeted therapies: déjà vu all over again |
| Q44066579 | Drug resistance: Time for mediation? |
| Q52649612 | ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells. |
| Q36544020 | Effects of a novel Nodal-targeting monoclonal antibody in melanoma |
| Q48240221 | Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing |
| Q36525065 | Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution. |
| Q35944399 | Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. |
| Q92621630 | Epithelial-Mesenchymal Transition in Skin Cancers: A Review |
| Q38939465 | Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells |
| Q90010888 | Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? |
| Q38901400 | Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance |
| Q34608239 | Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders |
| Q60300502 | Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis |
| Q26785389 | Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer |
| Q33629325 | FAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis. |
| Q39148508 | FOXO3 is essential for CD44 expression in pancreatic cancer cells. |
| Q42397458 | Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation |
| Q59260470 | Genetic and Genomics of Uterine Myomas |
| Q39340411 | Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers |
| Q27694704 | Genetic screens and functional genomics using CRISPR/Cas9 technology |
| Q38131166 | Genetics and biomarkers in personalisation of lung cancer treatment |
| Q36040827 | Genome-scale CRISPR pooled screens |
| Q29616044 | Genome-scale CRISPR-Cas9 knockout screening in human cells |
| Q34043392 | Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis |
| Q90372233 | Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition |
| Q41833143 | Genome-wide chromatin interactions of the Nanog locus in pluripotency, differentiation, and reprogramming |
| Q37662261 | Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations |
| Q38725577 | Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential |
| Q35180495 | High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients |
| Q33558230 | Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis |
| Q38717741 | Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer. |
| Q92422402 | Identifying Cancers Impacted by CDK8/19 |
| Q33889355 | Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker |
| Q64994221 | Importance of genetic screens in precision oncology. |
| Q35250612 | In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. |
| Q28573830 | In-cell intrabody selection from a diverse human library identifies C12orf4 protein as a new player in rodent mast cell degranulation |
| Q35739691 | Increased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy |
| Q36141923 | Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab |
| Q64114119 | Interaction map of Arabidopsis Mediator complex expounding its topology |
| Q90457405 | Intracellular and extracellular TGF-β signaling in cancer: some recent topics |
| Q52328749 | JMJD6 Licenses ERα-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex. |
| Q35645874 | Keratoconus in vitro and the key players of the TGF-β pathway. |
| Q38717980 | Knockdown of mediator subunit Med19 suppresses bladder cancer cell proliferation and migration by downregulating Wnt/β-catenin signalling pathway |
| Q37161750 | Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms |
| Q35832402 | Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis |
| Q38968909 | MED12 is recurrently mutated in Middle Eastern colorectal cancer. |
| Q36284814 | MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs |
| Q37708965 | MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways |
| Q36923130 | MED12 mutations in human diseases |
| Q35674474 | MED30 Regulates the Proliferation and Motility of Gastric Cancer Cells |
| Q47223150 | MRAS: A Close but Understudied Member of the RAS Family |
| Q53112710 | Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. |
| Q38622874 | Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology |
| Q37707244 | Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression |
| Q34348002 | Mediator complex dependent regulation of cardiac development and disease |
| Q26800203 | Mediator kinase module and human tumorigenesis |
| Q47073703 | Mediator subunit 12 coordinates intrinsic and extrinsic control of epithalamic development |
| Q38854881 | Mediator: A key regulator of plant development |
| Q42977115 | Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. |
| Q39016680 | MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer |
| Q34078212 | Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients |
| Q34365632 | Molecular pathways and targets in prostate cancer |
| Q55420715 | Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression. |
| Q39195305 | Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells |
| Q36340886 | Myoepithelial carcinoma with RB1 mutation: remarkable chemosensitivity to carcinoma of unknown origin therapy |
| Q26746478 | NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? |
| Q37588549 | Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition |
| Q52430564 | New tools for old drugs: Functional genetic screens to optimize current chemotherapy. |
| Q27324745 | Non-Darwinian dynamics in therapy-induced cancer drug resistance |
| Q38474990 | Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'. |
| Q41561954 | Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. |
| Q50026564 | Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of Cyclin C-CDK8/19. |
| Q26775594 | Other targeted drugs in melanoma |
| Q55280343 | Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer. |
| Q26866517 | Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance |
| Q35081779 | Phenotype switching in melanoma: implications for progression and therapy |
| Q41579911 | Phosphorylation of the translation initiation factor eIF2α at serine 51 determines the cell fate decisions of Akt in response to oxidative stress |
| Q51239492 | Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? |
| Q50767285 | Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery Platform. |
| Q61804782 | Predict drug sensitivity of cancer cells with pathway activity inference |
| Q35036012 | Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK |
| Q38918710 | Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification |
| Q36525647 | RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. |
| Q34960186 | RNA polymerase II transcription elongation control |
| Q33572728 | Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer |
| Q90750142 | Regulatory functions of the Mediator kinases CDK8 and CDK19 |
| Q36189390 | Resistance to targeted cancer drugs through hepatocyte growth factor signaling |
| Q27852990 | Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma |
| Q47096314 | Role of Transforming Growth Factor β in Uterine Fibroid Biology |
| Q38912433 | SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer |
| Q35833001 | Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation |
| Q47357292 | Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation |
| Q91708481 | Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients |
| Q35845827 | Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. |
| Q38915720 | Signaling Receptors for TGF-β Family Members |
| Q38726268 | Silencing Med12 Gene Reduces Proliferation of Human Leiomyoma Cells Mediated via Wnt/β-Catenin Signaling Pathway |
| Q35940471 | Single Chain Antibodies as Tools to Study transforming growth factor-β-Regulated SMAD Proteins in Proximity Ligation-Based Pharmacological Screens |
| Q51216583 | Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry. |
| Q53195350 | Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms. |
| Q74435535 | Switching off cancer resistance |
| Q48530618 | Systematic Gene-to-Phenotype Arrays: A High-Throughput Technique for Molecular Phenotyping |
| Q41272730 | TGF-β in pancreatic cancer initiation and progression: two sides of the same coin |
| Q41499355 | TGF-β induces p53/Smads complex formation in the PAI-1 promoter to activate transcription |
| Q49488316 | TGF-β signaling in cancer metastasis. |
| Q90970897 | TGF-β-induced alternative splicing of TAK1 promotes EMT and drug resistance |
| Q39105549 | TGF-β: an emerging player in drug resistance |
| Q28075605 | TGFΒ-induced transcription in cancer |
| Q94461885 | TGFβ and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness |
| Q97867213 | TGFβ biology in cancer progression and immunotherapy |
| Q39739202 | TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype |
| Q38241602 | TGFβ: A player on multiple fronts in the tumor microenvironment. |
| Q47712719 | Targeted next-generation sequencing of malignant peripheral nerve sheath tumor of the pterygopalatine fossa with intracranial metastatic recurrence |
| Q27022852 | Targeted therapies in development for non-small cell lung cancer |
| Q39155151 | Targeting TGF-β Signaling for Therapeutic Gain |
| Q39441327 | Targeting TGF-β Signaling in Cancer |
| Q104795035 | Targeting TGFβ signal transduction for cancer therapy |
| Q42419178 | Targeting survivin as a potential new treatment for chondrosarcoma of bone |
| Q37736262 | Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells |
| Q36938987 | The Mediator Complex and Lipid Metabolism |
| Q28299679 | The Mediator complex and transcription regulation |
| Q35131077 | The Mediator complex of Caenorhabditis elegans: insights into the developmental and physiological roles of a conserved transcriptional coregulator |
| Q26849595 | The Mediator complex: a central integrator of transcription |
| Q40996773 | The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells |
| Q21246017 | The basal transcription machinery as a target for cancer therapy |
| Q92207058 | The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics |
| Q27325648 | The evolutionarily conserved mediator subunit MDT-15/MED15 links protective innate immune responses and xenobiotic detoxification |
| Q52430211 | The mediator complex in genomic and non-genomic signaling in cancer. |
| Q61812007 | The nuclear hormone receptor NHR-86 controls anti-pathogen responses in C. elegans |
| Q33725976 | The quest to overcome resistance to EGFR-targeted therapies in cancer |
| Q37197845 | TrAp: a tree approach for fingerprinting subclonal tumor composition |
| Q42316815 | Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming |
| Q38762901 | Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer |
| Q60921660 | Transforming of the Tumor Microenvironment: Implications for TGF- Inhibition in the Context of Immune-Checkpoint Therapy |
| Q35219539 | Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures |
| Q34041747 | Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation |
| Q38190872 | Tumor cell plasticity: the challenge to catch a moving target |
| Q92502928 | Tumour-associated neutrophils in patients with cancer |
| Q24619675 | Update in lung cancer and mesothelioma 2012 |
| Q36935561 | Vitamin D3 Inhibits Wnt/β-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells |
| Q37465944 | ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma |
| Q35291824 | miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. |
Search more.